127 related articles for article (PubMed ID: 32300408)
1. Clinical Resolution of Red Cell Aplasia Associated del 17p Multiple Myeloma, When Treated With Bortezomib and Dexamethasone.
Ladha A; Fudym Y; Gentile TC
J Hematol; 2018 Jan; 7(1):29-31. PubMed ID: 32300408
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pure red cell aplasia associated with multiple myeloma with biclonal gammopathy using cyclosporine A: a case report.
Lv Y; Qian W
Int J Clin Exp Med; 2015; 8(1):1498-500. PubMed ID: 25785163
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).
Liu J; Yang H; Liang X; Wang Y; Hou J; Liu Y; Wang J; Zhou F
Oncotarget; 2017 Sep; 8(37):62435-62444. PubMed ID: 28977957
[TBL] [Abstract][Full Text] [Related]
5. Pure Red Cell Aplasia Associated With Thymoma.
Thangatorai R
Cureus; 2023 May; 15(5):e39387. PubMed ID: 37362458
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.
Noto R; Kamiura N; Ono Y; Tabata S; Hara S; Yokoi H; Yoshimoto A; Yanagita M
BMC Nephrol; 2017 Apr; 18(1):127. PubMed ID: 28385149
[TBL] [Abstract][Full Text] [Related]
8. 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
Lee J; Smith D; Rabin N; Tobias J; Yong K
Hematol Oncol; 2016 Sep; 34(3):165-70. PubMed ID: 26073569
[TBL] [Abstract][Full Text] [Related]
9. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
10. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
[TBL] [Abstract][Full Text] [Related]
11. Extramedullary Multiple Myeloma: A Patient-Focused Review of the Pathogenesis of Bone Marrow Escape.
Gupta S; Master S; Graham C
World J Oncol; 2022 Oct; 13(5):311-319. PubMed ID: 36406195
[TBL] [Abstract][Full Text] [Related]
12. Disease-controlled multiple myeloma in a patient with 17p gain and t(4;14): A case report.
Tang X; Xu R; Zheng W; Zhou Y; Cui S; Wang Y
Heliyon; 2024 Apr; 10(7):e28950. PubMed ID: 38596106
[TBL] [Abstract][Full Text] [Related]
13. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
Grannis CH; Dewan VN; Wang RC
Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
[TBL] [Abstract][Full Text] [Related]
14. Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment.
Vo AK; Kollsete Gjelberg H; Hovland R; Lindstad Brattås MK; Bruserud Ø; Reikvam H
Case Rep Hematol; 2020; 2020():1262038. PubMed ID: 32082654
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
16. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Nozza A; Siracusano L; Armando S
Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
[TBL] [Abstract][Full Text] [Related]
18. Treatment of coexisting chronic neutrophilic leukemia and light chain multiple myeloma with hydroxyurea, bortezomib, and dexamethasone.
Taiwo E; Wang H; Lewis R
Case Rep Hematol; 2014; 2014():869395. PubMed ID: 25143840
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
20. Genomic stratification of multiple myeloma treated with novel agents.
Jiang A; Reece D; Chang H
Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
